The global prediabetes market size is calculated at USD 300.42 million in 2025 and is forecasted to reach around USD 599.34 million by 2034, accelerating at a CAGR of 7.15% from 2025 to 2034. The North America prediabetes market size surpassed USD 123.17 million in 2024 and is expanding at a CAGR of 7.28% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Prediabetes Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Prediabetes Market, by Drug Class
8.1.1. Diguanide
8.1.1.1. Market Revenue and Forecast
8.1.2. Thiazolidinediones
8.1.2.1. Market Revenue and Forecast
8.1.3. Glucagon-like Peptide-1 Agonists (GLP-1)
8.1.3.1. Market Revenue and Forecast
8.1.4. SGLT2 Inhibitors
8.1.4.1. Market Revenue and Forecast
8.1.5. DPP-4 Inhibitors
8.1.5.1. Market Revenue and Forecast
8.1.6. Others
8.1.6.1. Market Revenue and Forecast
9.1. Prediabetes Market, by Age Group
9.1.1. Children (12-18 years)
9.1.1.1. Market Revenue and Forecast
9.1.2. Adults (18-49)
9.1.2.1. Market Revenue and Forecast
9.1.3. Elderly (50+)
9.1.3.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class
10.1.2. Market Revenue and Forecast, by Age Group
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class
10.1.3.2. Market Revenue and Forecast, by Age Group
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class
10.1.4.2. Market Revenue and Forecast, by Age Group
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class
10.2.2. Market Revenue and Forecast, by Age Group
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class
10.2.3.2. Market Revenue and Forecast, by Age Group
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class
10.2.4.2. Market Revenue and Forecast, by Age Group
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class
10.2.5.2. Market Revenue and Forecast, by Age Group
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class
10.2.6.2. Market Revenue and Forecast, by Age Group
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class
10.3.2. Market Revenue and Forecast, by Age Group
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class
10.3.3.2. Market Revenue and Forecast, by Age Group
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class
10.3.4.2. Market Revenue and Forecast, by Age Group
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class
10.3.5.2. Market Revenue and Forecast, by Age Group
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class
10.3.6.2. Market Revenue and Forecast, by Age Group
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class
10.4.2. Market Revenue and Forecast, by Age Group
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class
10.4.3.2. Market Revenue and Forecast, by Age Group
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class
10.4.4.2. Market Revenue and Forecast, by Age Group
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class
10.4.5.2. Market Revenue and Forecast, by Age Group
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class
10.4.6.2. Market Revenue and Forecast, by Age Group
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class
10.5.2. Market Revenue and Forecast, by Age Group
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class
10.5.3.2. Market Revenue and Forecast, by Age Group
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class
10.5.4.2. Market Revenue and Forecast, by Age Group
11.1. SciMar
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Boston Therapeutics
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Valbiotis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. RESVERLOGIX
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Caelus Health
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Aphaia Pharma
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. AstraZeneca
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bristol-Myers Squibb
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample